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Cancer-Causing Human Papillomavirus E6 Proteins Display Major
Differences in the Phospho-Regulation of Their PDZ Interactions
Siaw Shi Boon,a Vjekoslav Tomaic´,a Miranda Thomas,a Sally Roberts,b Lawrence Banksa
International Centre for Genetic Engineering and Biotechnology, Trieste, Italya; School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdomb
ABSTRACT
Previous studies have shown that the cancer-causing high-risk human papillomavirus (HPV) E6 oncoproteins have PDZ binding
potential, an activity which is important for their ability to support the viral life cycle and to cooperate in the induction of malig-
nancy. However, PDZ interactions are not constitutive, and they can be negatively regulated by phosphorylation within the E6
PDZ binding motif (PBM). In this study, we have investigated the differential regulation of the HPV E6 PBMs from diverse high-
risk HPV types. We show that, depending on the HPV type, PDZ binding activity can be regulated by phosphorylation with pro-
tein kinase A (PKA) or AKT, which, in turn, inhibits PDZ recognition. Such regulation is highly conserved between E6 proteins
derived fromHPV-16, HPV-18, and HPV-58 while being somewhat weaker or absent from other types such as HPV-31, HPV-33,
and HPV-51. In the case of HPV31, PKA phosphorylation occurs within the core of the E6 protein and has no effect on PDZ in-
teractions, and this demonstrates a surprising degree of heterogeneity among the different high-risk HPV E6 oncoproteins in
how they are regulated by different cellular signaling pathways.
IMPORTANCE
This study demonstrated that the cancer-causing HPV E6 oncoproteins are all subject to posttranslational modification of their
extreme C-terminal PDZ binding motifs through phosphorylation. However, the identities of the kinase are not the same for all
HPV types. This demonstrates a very important divergence between these HPVs, and it suggests that changes in cell signaling
pathways have different consequences for different high-risk virus infections and their associated malignancies.
Human papillomaviruses (HPVs) are the causative agents ofcervical cancer, which remains a leading cause of death in
women throughout the world. Over 120 different HPV types have
been identified, 12 ofwhich are defined as cancer causing (1, 2).Of
these, HPV-16 and HPV-18 are the most important, accounting
for approximately 70% of cervical cancers. The remaining cancers
are caused by other high-risk (HR) HPV types, which include
HPV-31, -33, -35, -51, -52, -58, -39, -45, -56, and -59 (1, 2). HPV-
induced carcinogenesis arises from the combined activity of the
two major viral oncoproteins E6 and E7, which, by deregulating
multiple cellular pathways, including cell cycle control and apop-
tosis, ultimately induce cell immortalization and, eventually, ma-
lignancy (3, 4).
A unique characteristic of the HR HPV E6 oncoproteins is the
presence of a class I PDZ (PSD-95/Dlg/ZO-1) binding motif
(PBM) at the extreme carboxy terminus, which is absent in the
low-risk (LR) non-cancer-causing HPV E6 proteins (5, 6). This
region of E6 allows it to interact with a number of cellular PDZ
domain-containing proteins, many of which are involved in the
regulation of cell junctional integrity and cell signaling pathways
(reviewed in reference 7). The first such targets to be identified
were the cell polarity regulators Discs Large (hDlg1) (5, 7, 8) and
Scribble (hScrib) (9), which were shown to be degraded by
HPV-16 and HPV-18 E6 in a proteasome-dependent manner.
However, subtle variations in the PBM sequences between
HPV-16 and HPV-18 E6 revealed differences in how diverse HPV
E6 oncoproteins interact with their PDZ substrates and indicated
that HPV-18 E6 preferentially associates with hDlg1, while
HPV-16 E6 preferentially binds hScrib (10).
The biological consequences of HPV E6 interaction with PDZ
domain-containing targets are very diverse (11). This interaction
has been reported to contribute toward the ability of E6 to immor-
talize rodent cells (8, 12) and human tonsillar keratinocytes (13),
and to promote epithelial-to-mesenchymal transition (EMT)
characteristics in human foreskin keratinocytes (14). In mice, this
region of E6 contributes to the cooperation with E7 in tumor
induction and plays an important role in the generation of malig-
nancy in both the cervix and the skin (15, 16). Mutations in this
region of E6 in the context of the whole viral genome result in
marked defects to the viral life cycle, with reduced rates of viral
DNA replication and a reduction in the expansion of replication-
competent cells in the basal layers of the organotypic cultures (17,
18). Furthermore, such viral genomes appear unstable over time,
with rapid loss of viral episomes upon continued passaging of the
cells (17–21).
Recognition of PDZ substrates by HPV-16 and HPV-18 E6 is
not constitutive and is subject to posttranslational regulation of
both E6 and the substrate (22–24). Depending on the specific
HPV type, the E6 PBM can be phosphorylated by either protein
kinase A (PKA) or AKT, resulting in disruption of E6 binding to
Received 4 July 2014 Accepted 5 November 2014
Accepted manuscript posted online 19 November 2014
Citation Boon SS, Tomaic´ V, Thomas M, Roberts S, Banks L. 2015. Cancer-
causing human papillomavirus E6 proteins display major differences in the
phospho-regulation of their PDZ interactions. J Virol 89:1579–1586.
doi:10.1128/JVI.01961-14.
Editor:M. J. Imperiale
Address correspondence to Lawrence Banks, banks@icgeb.org.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.01961-14
February 2015 Volume 89 Number 3 jvi.asm.org 1579Journal of Virology
 o
n
 January 12, 2015 by UNIV O
F BIRM
ING
HAM
http://jvi.asm.org/
D
ow
nloaded from
 
PDZ-containing targets (23, 25). Moreover, we recently showed
that this phosphorylated E6 could instead interact with 14-3-3
(23), a phospho-serine/threonine binding protein (26). There are
seven different isoforms of 14-3-3, which play diverse roles in the
regulation of cellular homeostasis, many of these functions being
relevant for cancer development (27–29). This suggests that the E6
PBM is actually bifunctional, mediating interaction with either
PDZ domain-containing substrates or 14-3-3 family members,
depending upon the E6 phosphorylation status. In this study, we
have analyzed the phospho-switch regulation of several E6 pro-
teins derived from cancer-causingHPV types.We have found that
phospho-regulation of the E6 PBM is a common theme, but the
mechanisms by which it occurs and the subsequent consequences
are quite diverse.
MATERIALS AND METHODS
Cell culture and transfections.HEK293 cells weremaintained inDulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum, penicillin-streptomycin (100 U/ml), and glutamine (300 g/ml).
Transient transfections were performed on approximately 7  105 cells
seeded in 60-mm dishes by standard calcium precipitation (30).
Plasmids. To generate glutathione S-transferase (GST) fusion pro-
teins, HPV-16, -18, and -31 E6 proteins were cloned into pGEX2T as
described previously (31–33). The HPV-33 E6-GST was subcloned di-
rectly from pcDNA-33 E6 into compatible BamHI and EcoRI restriction
sites of pGEX2T. The HPV-51 E6-GST was generated by mutational al-
teration of the HPV-18 E6 PBM to match the PBM of HPV-51, while
HPV-58, HPV-31 E6 delPDZ, and HPV-31 E6 T145AdelPDZ fusion pro-
teins were generated by subcloning PCR-amplified HPV-58 and HPV-31
E6 into compatible BamHI and EcoRI restriction sites of pGEX2T. Primer
sequences used are as follows: for HPV-51 E6, TTTGGATCCATGGCGC
GCTTTGAGGATCCA (forward) and GAATTCTACTTGCGTTTCAT
TGCG (reverse); for HPV-58 E6, ATGGATCCATGTTCCAGGACGC
AGAG (forward) and CGGAATTCTTACACTTGTGTTTGTCTGC
(reverse); for HPV-31 delPDZ, CCGGATCATGTTCATCAAAAATC
(forward) and CCGAATTCTTAAGTACGAGGT (reverse); and for
HPV-31 T145AdelPDZ, CCGGATCATGTTCATCAAAAATC (forward)
and CCGAATTCTTATGCACGAGTC (reverse).
Resulting plasmids were all verified by DNA sequencing. These HPV-
16, HPV-18, HPV-31, HPV-33, HPV-18:HPV-51, and HPV-58 E6 pro-
teins as well as HPV-31 E6mutants are all depicted schematically in Fig. 1.
TheDlg andMAGI-1 expression plasmids have been described previously
(7, 34).
In vitro phosphorylation and binding assays. GST fusion proteins
were washed with 1 phosphate-buffered saline (PBS) containing 0.1%
Tween 20, followed by twowashes twicewith the respective kinase buffers.
The buffers used are as follows: PKA buffer containing 25 mM Tris HCl
(pH 7.5), 10 mMMgCl2, and 70mMNaCl and AKT buffer containing 25
mM Tris HCl (pH 7.5), 10 mMMgCl2, and 5 mM dithiothreitol (DTT).
In vitro phosphorylation of the fusion proteins was carried out using
20 l of kinase buffer containing 2.5 Ci of radiolabeled 32-ATP and 25
U of cAMP-dependent protein kinase catalytic subunit (Promega) for 20
min at 30°C, or 0.2 g of AKT1 and 4 l of reaction buffer A from AKT1
kinase enzyme system (Promega) at 30°C for 45 min.
Purified GST fusion proteins (before and after phosphorylation with
cold ATP) were incubated with in vitro-translated and radiolabeled Dlg
andMAGI-1 or with purified His-tagged 14-3-3ε isoform (Enzolife) for 1
h at room temperature. After a wash with PBS containing 0.1%Tween 20,
the boundDlg andMAGI-1were subjected to SDS-PAGE and analyzed by
autoradiography, while 14-3-3 proteins were detected by Western blot-
ting using anti-14-3-3-specific antibodies.
Immunoprecipitation.HEK293 cells (7 105) were seeded onto 10-
cm2 dishes and transfected with 10 g of HA-tagged HPV-18 E6 using
calcium phosphate precipitation (30). Twenty-four hours posttransfec-
tion, the cells were collected and lysed using high-salt E1Abuffer (500mM
NaCl, 0.1% NP-40, and 50 mM HEPES [pH 7.0]) in the presence of
protease and phosphatase inhibitors, followed by gentle syringing and
then incubation on ice for 20 min. Cell lysates were then centrifuged at
14,000 rpm for 10 min. The extracted lysates were either pretreated with
2,000 U of  phosphatase (NEB) at 30°C for 15 min or incubated directly
with 30 l of monoclonal antihemagglutinin (anti-HA)-conjugated aga-
rose beads (Sigma) at 4°C for 3 h. Samples were washed thrice with E1A
buffer and then subjected to Western blot analysis.
Antibodies andWestern blotting. The anti-phospho-E6-specific an-
tibody (custom-made by Eurogentec [23]) was raised against the peptide
H2N-RQERLQRRRET(PO3H2)QV-COOH in rabbits. For detection of
phospho-E6 in a Western blot using this antibody, blocking was done
using 3% bovine serum albumin (BSA) in 1 Tris-buffered saline (TBS)
containing 0.1% Tween 20 (1 TBST) with gentle rocking at 4°C for 1 h.
The blot was then incubated with anti-phospho-E6-specific antibody di-
luted in 3% BSA in 1 TBST (1:500) overnight with gentle rocking. The
blot was washed thrice with 1 TBST and incubated with anti-rabbit
horseradish peroxidase (HRP;Dako)-conjugated antibody anddeveloped
using the ECL detection system (Amersham).
The following antibodies were also used: mouse anti-6His (BD Bio-
sciences); rabbit anti-14-3-3, -14-3-3ε, -14-3-3, and -14-3-3 (all from
Santa Cruz); mouse anti-HA; and appropriate secondary antibodies con-
jugated to horseradish peroxidase (Dako).
RESULTS
Phosphorylation of the E6 PBM is conserved across multiple
HPV types. Previous studies have shown that HPV-18, HPV-16,
and HPV-31 E6 can be phosphorylated within the PBM, although
the identity of the kinase involved, PKAorAKT, depends upon the
composition of the PBM, and this can vary (Fig. 1) between dif-
ferent HPV types (23). We were interested in extending these
studies to E6 proteins derived from other HPV types to determine
whether phospho-regulation of the PBM was a conserved feature
among high-risk HPV E6 proteins. To do this, we used HPV-33,
-51, and -58 E6 proteins expressed as GST fusion proteins, with
HPV-16, -18, and -31 E6-GST fusion proteins for comparison.
The purified proteins were incubated with commercially available
purified active PKA or AKT together with radiolabeled ATP. The
FIG 1 Consensus motifs in the carboxy-terminal regions of diverse HPV E6
oncoproteins. Shown are the amino acid sequences of the C-terminal PDZ
binding motifs (PBMs) of HPV-18, -16, -31, -33, -51, and -58, together with
the HPV-31 E6 mutant derivatives delPDZ and T145AdelPDZ. At the top are
shown the consensus recognition sequences for phosphorylation by PKA (36)
and AKT (37). Also shown is the consensus PDZ binding motif.
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levels of E6 phosphorylation were then ascertained by SDS-PAGE
and autoradiography. The results in Fig. 2A demonstrate that
HPV-18 E6 is the most susceptible to phosphorylation by PKA,
closely followed by HPV-58 E6. HPV-33, -51, and -31 E6 proteins
are all somewhat weaker substrates for PKA. In the case of AKT,
HPV-16 E6 and HPV-58 E6 are most readily phosphorylated.
HPV-31 E6 then follows, withHPV-33 andHPV-51 E6 being very
poor substrates for AKT (Fig. 2B). These results demonstrate that
while all the high-riskHPVE6proteins analyzed can be phosphor-
ylatedwithin the PBM, there aremajor differences in the efficiency
with which this occurs.
Analysis of the HPV-31 E6 carboxy-terminal sequence (Fig. 1)
indicates the existence of two potential phospho-acceptor sites
(threonine residues) within this region: one within the PBM and
one located just upstream. This seemed particularly interesting,
since phosphorylation of T145 upstream of the PBM would be
unlikely to affect PDZ recognition, while T147 would most likely
be inhibitory (23, 35). Therefore, to identify which of these poten-
tial sites was phosphorylated, we generated two mutations within
the HPV-31 E6 carboxy terminus (see Fig. 1). The purified GST
fusion proteins were then subjected to phosphorylation with PKA
and AKT; the results obtained are shown in Fig. 3. As can be seen,
mutation of both potential phospho-acceptor sites in HPV-31 E6
has no effect on the levels of PKA phosphorylation (Fig. 3A). Al-
though mass spectrometry analysis of PKA-phosphorylated
HPV-31 E6 indicated that the potential phospho-acceptor site was
S82, the mutant derivative S82A could still nonetheless be phos-
phorylated by PKA, indicating that HPV-31 E6 is phosphorylated
by PKA at more than one site (data not shown). In contrast, the
AKT phosphorylation would appear to occur primarily on the
carboxy-terminal threonine, lying within the PBM (Fig. 3B).
To confirm these results, we performed Western blot analysis
using antibodies raised against phospho-HPV-18 E6 to determine
whether they could also similarly detect HPV-31 and HPV-58
phosphorylated E6 (23). The results in Fig. 3C demonstrate that
PKA-phosphorylated HPV-18 and HPV-58 E6 proteins are read-
ily detected by the anti-phospho-E6-specific antibody. In con-
trast, PKA-phosphorylated HPV-31 E6 is not detected by this an-
tibody, consistent with the HPV-31 E6 PKA phospho-acceptor
site lying outside the PBM. In contrast, it is clear that wild-type
HPV-31 E6 phosphorylated by AKT is recognized by the anti-
phospho-E6 antibody, whereas the two carboxy-terminalmutants
of E6 are not (Fig. 3D).
Taken together, these results indicate that while HPV-31 E6
can be phosphorylated by both AKT and PKA, the phospho-
acceptor sites are not the same, and only AKT phosphorylates
HPV-31 within the PBM. In contrast, HPV-16 (23) and
HPV-58 E6 proteins are phosphorylated in the PBM by both
AKT and PKA.
Phosphorylation of E6 negatively regulates interaction with
Dlg and MAGI-1. Previous studies showed that PKA phosphory-
lation of HPV-18 E6 negatively regulates its interaction with Dlg
(25) andMAGI-1 (23). While phosphorylation of PBMs is gener-
ally assumed to inhibit PDZ recognition (35), we wanted to ascer-
tain whether the other high-risk HPV E6 oncoproteins were sub-
jected to a similar pattern of regulation. To do this, we performed
a series of in vitro pulldown assays using phosphorylated GST-E6
and in vitro-translated radiolabeledMAGI-1. The results obtained
are shown in Fig. 4 and demonstrate a number of interesting fea-
tures. Although there are variations in the degree to which the
different E6 proteins bindMAGI-1, withHPV-18 andHPV-58 E6
being the strongest, the phosphorylation of HPV-18, -33, -51, and
-58 E6 proteins decreased the ability of all to interact withMAGI-1
(Fig. 4A). However, HPV-31 E6 appears to differ: its interaction
withMAGI-1 is comparable to that of HPV-18 E6, but PKA phos-
phorylation has no effect on the interaction (Fig. 4B). This is con-
sistent with the above-described results showing that HPV-31 E6
is phosphorylated by PKA outside the PBM (Fig. 3A and C). Sim-
ilar results were also seen with Dlg (Fig. 4C). In both cases, the
PBM mutation confirmed that HPV-31 E6 PDZ interactions are
mediated through classic PBM recognition (Fig. 4B and C). These
results demonstrate that although the PDZ recognition of most
HPV E6 oncoproteins is negatively regulated by PKA, this does
not hold true for HPV-31 E6.
We then repeated this analysis followingAKTphosphorylation
of the different GST-E6 fusion proteins andmonitored the effects
on interactions with Dlg. The results obtained are shown in Fig.
4D and are again a clear reflection of the capacity of the different
E6 proteins to be phosphorylated by AKT within their PBMs.
Thus, HPV-18 and HPV-33 E6 are very poor substrates of AKT,
and not surprisingly, AKT phosphorylation has no effect on their
ability to interact with Dlg. In contrast, HPV-16 and HPV-58 E6
proteins are very good substrates of AKT, and this is reflected in
the effects on Dlg recognition, where phosphorylation greatly re-
duces the interaction with the two E6 proteins. As noted above,
FIG 2 High-risk HPV E6 oncoproteins are phosphorylated by PKA or AKT.
(A) Purified GST fusion proteins of HPV-18, -33, -51, -58, and -31 E6, either
left untreated () or incubated with PKA (	) and 32P-ATP as indicated.
Proteins were analyzed by SDS-PAGE and autoradiography. (B) HPV-16, -33,
-51, -58, and -31 E6-GST fusion proteins, either left untreated () or treated
with AKT (	) and 32P-ATP as indicated. In each case the upper portions
show the autoradiograms and the lower portions show the Coomassie-stained
gels. Arrows indicate the relevant proteins.
Phospho-Regulation of HPV E6
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HPV-31 E6 is phosphorylated by AKT on the threonine residue
embedded within the PBM, and not surprisingly, this also results
in a strong inhibition of HPV-31 E6 interaction with Dlg. Taken
together, these results demonstrate that the capacities of different
HPV E6 oncoproteins to be phosphorylated by different cellular
kinases vary considerably among the different high-risk HPV E6
oncoproteins, but the consequences of such phosphorylation
events within the E6 PBM are always the same, resulting in an
inhibition of E6 PBM PDZ interactions.
Recognition of 14-3-3 family members is conserved among
multiple high-risk HPV E6 oncoproteins. The above-described
studies indicate that phosphorylation of the E6 PBM is a common
theme in the regulation of E6 function and negatively regulates
interaction with PDZ domain-containing substrates. We previ-
ously showed that HPV-18 E6 phosphorylated within the PBM
could, however, interact with 14-3-3. Since there are seven dif-
ferent isoforms of 14-3-3, we were next interested in determining
whether the other high-risk HPV E6 oncoproteins could also as-
sociate with 14-3-3 in a similar manner. In order to first ascertain
which were themost relevant isoforms to analyze, we performed a
series of studies to determine which isoforms could be preferen-
tially bound to HPV-18 E6 in vivo. To do this, HEK293 cells were
transfectedwith aHA-taggedHPV-18 E6 expression plasmid, and
after 24 h, the cells were harvested and extracts immunoprecipi-
tated using anti-HA antibody-conjugated agarose beads. Any co-
immunoprecipitating 14-3-3 family members were then detected
by Western blot analysis using isoform-specific antibodies. The
results obtained are shown in Fig. 5A and demonstrate that
HPV-18 E6 can strongly interact with 14-3-3, in agreement with
our previous observations. Interestingly, additional 14-3-3 iso-
forms were also identified in complex with HPV-18 E6, and these
included 14-3-3ε and 14-3-3, with much weaker interaction ob-
tained with 14-3-3. However, little or no interaction was de-
FIG 3 HPV-31 E6 is differentially phosphorylated by PKA and AKT. (A) Purified GST fusion proteins of HPV-31 E6 wild-type and PBMmutants, delPDZ and
T145AdelPDZ, either left untreated () or incubatedwith PKA (	) and 32P-ATP as indicated. Proteins were analyzed by SDS-PAGE and autoradiography. The
upper portion shows the autoradiogram, and the lower portion shows the Coomassie stain of the gel. (B) Experiment similar to that for panel A, but GST fusion
proteins were either left untreated () or incubatedwith AKT (	). (C)HPV-18, -31, and -58 E6-GST fusion proteins, either left untreated () or incubatedwith
PKA (	) in the presence of cold ATP. These were detected byWestern blotting using anti-phospho-E6-specific antibody. The lower portion shows the Ponceau
stain of the nitrocellulosemembrane confirming equal levels of protein loading. (D) A similar analysis of GST fusion proteins ofHPV-16 E6, HPV-31 E6, and the
HPV-31 E6 mutants, delPDZ and T145AdelPDZ, either left untreated () or incubated with AKT (	) and detected by Western blotting using anti-phospho-
E6-specific antibody. Arrows indicate the relevant GST proteins.
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tected between HPV-18 E6 and 14-3-3
 or 14-3-3 (data not
shown).
In order to confirm that the ability of E6 to complex with
14-3-3 isoforms in vivowas dependent upon the phosphorylation
of the E6 oncoprotein, we repeated the coimmunoprecipitation
assay between HA-tagged HPV-18 E6 and 14-3-3ε, but in this
case, we also pretreated the cell extracts with  phosphatase to
remove phosphate groups fromHPV-18 E6. The results in Fig. 5B
demonstrate that  phosphatase treatment results in a dramatic
reduction in the ability of E6 to interact with 14-3-3ε, and this is
reflected in themarked decrease in the levels of phospho-E6, while
total E6 levels remain unchanged. Taken together, these results
FIG 4 PKA and AKT phosphorylation negatively regulates interaction of HPV E6 with PDZ domain-containing proteins. (A and B) The indicated GST fusion
proteins were either left untreated () or subjected to phosphorylation with PKA (	) in the presence of cold ATP. These were then incubated with in
vitro-translated radiolabeled MAGI-1. Following extensive washing, the bound MAGI-1 was detected using SDS-PAGE and autoradiography (shown in the
upper portion). The lower panels in each case show the Coomassie stain of the gels; arrows indicate the relevant proteins. (C) The indicated GST fusion proteins
were either left untreated () or subjected to phosphorylation with PKA (	) in the presence of cold ATP. These were then incubated with radiolabeled in
vitro-translatedDlg as indicated. Following extensive washing, bound proteins were detected using SDS-PAGE and autoradiography shown in the upper portion.
The lower portion shows the Coomassie stain of the gel. The arrows indicate the relevant fusion proteins and in vitro-translated products. (D) Same as in panel
C except that the E6 fusion proteins were phosphorylated with AKT (	) in the presence of cold ATP and subsequent interaction with Dlg was then assessed by
SDS-PAGE and autoradiography.
FIG 5 HPV-18 E6 interacts with multiple 14-3-3 isoforms in vivo in a phosphorylation-dependent manner. (A) HEK293 cells were transfected with HA-tagged
HPV-18 E6 expression plasmid. After 24 h, the cells were extracted and immunoprecipitated (IP) with anti-HA-conjugated agarose beads, and coprecipitating
14-3-3 isoforms were detected byWestern blotting. Also shown is the anti-HA (-HA) blot for total E6 and anti-phospho-E6 (-pE6), and the right side shows
the protein inputs for the different 14-3-3 isoforms. Note the strong interaction of E6with 14-3-3, 14-3-3ε, and 14-3-3. (B)HEK293 cells were transfectedwith
HA-tagged HPV-18 E6; after 24 h, cell extracts were treated (	) with  phosphatase (Ppase) or not () for 15 min as indicated and then immunoprecipitated
with anti-HA-conjugated agarose beads. Bound 14-3-3ε was detected by Western blotting. Also shown is the anti-HA blot for total E6 and anti-phospho-E6.
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indicate that HPV-18 E6 can interact, in a phosphorylation-de-
pendent manner, with a defined subset of 14-3-3 isoforms in vivo.
We then wanted to ascertain whether the other high-risk HPV
E6 oncoproteins could also interact with 14-3-3 in a phosphory-
lation-dependent manner. In order to do this, the different
GST-E6 fusion proteins were purified and phosphorylated using
either AKT or PKA. The E6 proteins were then incubated with
commercially available, affinity-purified His-tagged 14-3-3ε, and
following extensive washing, bound 14-3-3 was detected byWest-
ern blotting. The results in Fig. 6Ademonstrate that all E6 proteins
that are good substrates of PKA are also able to interact strongly
with 14-3-3ε postphosphorylation. Likewise, E6 proteins that are
good substrates of AKT also interact strongly with 14-3-3ε (Fig.
6B) postphosphorylation. Taken together, these results demon-
strate that the E6 PBM of multiple HPV types has dual functions
and, depending upon the phosphorylation status, can confer in-
teraction with either PDZ domain-containing proteins or mem-
bers of the 14-3-3 protein family.
To investigate this further, we then performed a comparative
coimmunoprecipitation analysis using HPV-16 and HPV-18 E6
proteins to determine whether there were similar differences in
their respective 14-3-3 interaction profiles in vivo. To do this,
HEK293 cells were transfected with HA-tagged HPV-16 and
HPV-18 E6 expression plasmids, and after 24 h, the cells were
harvested and immunoprecipitated with anti-HA-conjugated
agarose beads.Western blots were then performed tomonitor the
levels of E6 phosphorylation using anti-phospho-E6 antibody and
14-3-3- and 14-3-3ε-specific antibodies to detect coimmunopre-
cipitating proteins. As can be seen fromFig. 6C,HPV-16 E6 shows
higher levels of phosphorylation than HPV-18 E6, in agreement
FIG 6 Diverse HPV E6 oncoproteins interact with 14-3-3 in a phosphorylation-dependent manner. Different HPV E6-GST fusion proteins were purified and
phosphorylated with either PKA (A) or AKT (B) in the presence of cold ATP. They were then incubated with purified 14-3-3ε, and after extensive washing, the
boundHis-tagged 14-3-3εwas detected byWestern blottingwith anti-6His antibody. The upper portions show the results of theWestern blots, while the lower
portions show Ponceau staining of the nitrocellulose membranes confirming equal levels of protein loading. Arrows show the locations of the relevant proteins.
(C) HEK293 cells were transfected with HA-tagged HPV-18 and HPV-16 E6 expression plasmids or empty plasmid. After 24 h, the cells were extracted and
immunoprecipitatedwith anti-HA-conjugated agarose beads, and coprecipitating 14-3-3 isoformswere detected byWestern blotting. Also shown is the anti-HA
blot for total E6 and anti-phospho-E6.
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with previous studies (23). Interestingly, similar levels of 14-3-3
are coimmunoprecipitated with both HPV-18 and HPV-16 E6,
while there seems to be weaker association between HPV-16 E6
and 14-3-3ε. These results are a good reflection of the in vitro
interaction assays and further support the notion that different E6
oncoproteins exhibit a specific preference for certain combina-
tions of 14-3-3 isoforms.
DISCUSSION
The presence of a PBM on the carboxy termini of cancer-causing
E6 oncoproteins is essential for the viral life cycle (17–21) and
contributes toward cell transformation (8, 13) and the induction
of malignancy (15, 16). While it has been known for some time
that this region of E6 could be phosphorylated, which, in turn,
would be expected to inhibit E6-PDZ interactions (23, 25), it has
only recently become clear that this phosphorylation also confers
upon E6 the ability to interact with 14-3-3 family members (23).
This indicates that phospho-regulation of E6 is critical in control-
ling the function of this important region of the E6 oncoprotein.
For this reason we have embarked upon a series of studies to
compare the relative susceptibility to phosphorylation of theHPV
E6 oncoproteins from a panel of different cancer-causing HPV
types. We find surprising differences between viruses in terms of
the levels of E6 phosphorylation, the identity of the phospho-
acceptor site, and the responsible kinase, with corresponding ef-
fects on PBM function.
Previous studies had suggested that there were significant dif-
ferences in how the HPV-16 and HPV-18 E6 oncoproteins were
phosphorylated by either PKA or AKT (23). To understand
whether phosphorylation of the E6 PBM is a common element in
the regulation of cancer-causing HPV E6 functions, we compared
the phosphorylation levels of six different HPV E6 oncoproteins.
Interestingly, HPV-16, HPV-18, HPV-58, and, to a lesser extent,
HPV-31 were all found to be good substrates for phosphorylation
by either PKA or AKT, and with the exception of HPV-31 E6 (see
below), the phospho-acceptor site was located in the PBM. Lower
levels of phosphorylationwere found forHPV-33 andHPV-51E6,
and we have not mapped the phospho-acceptor sites on these two
E6 proteins. Whether this reflects intrinsically low levels of phos-
phorylation, or other phospho-acceptor sites, or indicates that
phosphorylationmay occur through an as-yet-unidentified kinase
remains to be determined. However, the consequences of phos-
phorylation for PDZ recognition were found to be similar be-
tween the different E6 oncoproteins, with phosphorylation of the
PBM, even if weak, leading to a reduction in PDZ binding poten-
tial. An interesting exception to this was found to be HPV-31 E6,
which has two potential phospho-acceptor sites within the last six
amino acids of its carboxy terminus. This protein is a substrate for
both AKT and PKA, but AKT would appear to phosphorylate the
downstream T147 within the PBM, while PKA phosphorylates
HPV-31 E6 outside the PBM at a residue(s) that remains to be
identified. This would tend to suggest that the activity of HPV-31
E6 is regulated differently from those of the other HPV E6 onco-
proteins that we have analyzed. Indeed, in the presence of PKA,
PDZ recognition by HPV-31 E6 was unaffected, since the PBM
was left unphosphorylated. Instead, phosphorylation of HPV-31
E6 occurred at S82, and it will now be of interest to determine how
this phosphorylation might affect the other activities of HPV-31
E6, such as E6AP recognition and p53 degradation. In contrast,
phosphorylation of HPV-31 E6 by AKT occurred on T147 within
the PBM and, as with HPV-16 E6 and HPV-58 E6, this results in
an inhibition of PDZ recognition. Whether these differences re-
flect differences in the pathologies found to be associated with
HPV-31 remains to be determined, but comparative studies on
the different viral life cycles in vitro should take these aspects into
consideration.
Having previously demonstrated that 14-3-3 was an interact-
ing partner of HPV-18 E6 in vivo (23), we wanted to determine
whether any of the other high-risk HPV E6 proteins shared the
capacity to interact with 14-3-3 in a phosphorylation-dependent
manner. Since there are seven 14-3-3 isoforms, we first deter-
mined which were recognized by HPV-18 E6 in vivo. We found
that 3 isoforms are bound strongly: 14-3-3, which is consistent
with our previous studies (23), plus 14-3-3ε and 14-3-3. These
isoforms all have important roles to play in diverse aspects of
cellular homeostasis (27–29), and it is now imperative to ascertain
how E6 interaction with these isoforms affects E6 activity and
14-3-3 functions. These findings have also facilitated a series of
studies to assess the ability of the other high-risk HPV E6 onco-
proteins to interact with 14-3-3 in a phosphorylation-dependent
manner.We show that phosphorylation of E6 negatively regulates
PDZ interactions, and instead confers interaction with 14-3-3ε in
a highly conserved manner across multiple HPV E6 types. Inter-
estingly, this is also a direct reflection of the susceptibility of a
given E6 protein to be phosphorylated by a particular kinase.
Taken together, these studies have defined a common mecha-
nism of regulation of diverse high-risk HPV E6 oncoproteins with
respect to the regulation of their PDZ and 14-3-3 interaction pro-
files. However, these studies have also revealed surprising differ-
ences in the forms in which these regulations take place, including
major differences in the kinases involved. These studies also high-
light the potential relevance of alterations in AKT and PKA signal-
ing pathways, both under different environmental conditions and
in different anatomical locations. Such alterations might have a
significant impact on the particular tropisms of different high-risk
HPV types, but they might also impact the likelihood of such
infections progressing to malignancy. Future studies will investi-
gate these aspects.
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